Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EE/LNG Clear all
Completed Phase 3 Interventional

Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder

NCT00128934
View directory record Official record
Conditions
Menstruation Disturbances, Premenstrual Syndrome
Interventions
levonorgestrel/ethinyl estradiol
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
69
States / cities
Scottsdale, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential

NCT06657105
View directory record Official record
Conditions
Healthy Participants
Interventions
EE/LNG, Baxdrostat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

NCT01243580
View directory record Official record
Conditions
Healthy
Interventions
Ortho-Cyclen, AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study Of AGILE AG200-15 After Weekly Application Under Various Conditions in Healthy Female Volunteers

NCT01375946
View directory record Official record
Conditions
Healthy
Interventions
AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Bleeding Patterns With Three Different Doses of DR-1031 Compared to Seasonale

NCT00394771
View directory record Official record
Conditions
Breakthrough Bleeding
Interventions
DR-1031, Seasonale®, Portia®
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
567 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
50
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2013 · Synced Oct 17, 2026, 4:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Quantification of Immune Cells in Women Using Contraception (CHIC II)

NCT01873170
View directory record Official record
Conditions
HIV, Immune Cells (Mucosal and Systemic), Contraception
Interventions
levonorgestrel exposure, DMPA exposure, etonogestrel exposure, IUD insertion, subdermal contraceptive implant insertion
Drug · Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women

NCT00319163
View directory record Official record
Conditions
Healthy
Interventions
levonorgestrel/ethinyl estradiol
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2009 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of AG200-15 Transdermal Patch to Three Anatomical Sites in Healthy Females

NCT01422135
View directory record Official record
Conditions
Healthy
Interventions
AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Lincoln, Nebraska • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

NCT07539090
View directory record Official record
Conditions
Healthy Participants
Interventions
Vimseltinib, Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants

NCT06942936
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5004, Itraconazole, EE/LNG
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

NCT06783192
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions
MK-8527, LNG/EE
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens

NCT00117273
View directory record Official record
Conditions
Healthy
Interventions
Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)], Seasonique (LNG/EE and EE), Portia (LNG/EE)
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System

NCT01181479
View directory record Official record
Conditions
Contraception
Interventions
AG200-15 (cycles 1-13), Lessina crossover to AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
17 Years to 40 Years · Female only
Enrollment
1,504 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
80
States / cities
Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

NCT07074327
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407, LNG/EE, NGM/EE, NET/EE, DRSP/EE
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

NCT04309643
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CTP-543, Combined oral contraceptive containing Ethinyl estradiol (EE) and Levonorgestrel (LNG)
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions

NCT06671405
View directory record Official record
Conditions
Dyslipidaemia
Interventions
AZD0780, Itraconazole, Carbamazepine, Midazolam, Ethinyl estradiol/levonorgestrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System

NCT07739589
View directory record Official record
Conditions
Residual Drug Amount of EE and LNG
Interventions
Twirla® (Levonorgestrel/Ethinyl Estradiol) Transdermal System
Drug
Lead sponsor
Insud Pharma
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

NCT06380205
View directory record Official record
Conditions
Healthy Participants
Interventions
Povorcitinib, Levonorgestrel/Ethinyl estradiol
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

NCT06071442
View directory record Official record
Conditions
Healthy Participants
Interventions
Vemircopan, Rosuvastatin, Metformin, Levonorgestrel / Ethinyl Estradiol, Carbamazepine
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Oral Contraceptives and Body Mass Index

NCT01170390
View directory record Official record
Conditions
Body Weight, Contraceptive Usage
Interventions
All participants (Aviane), Portia, Aviane
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

NCT00781456
View directory record Official record
Conditions
Migraine
Interventions
91-day Levonorgestrel Oral Contraceptive, Placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
La Mesa, California • San Diego, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

NCT06793943
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Zasocitinib, COC, Metformin, Digoxin, Esomeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm

NCT01236768
View directory record Official record
Conditions
Contraception
Interventions
AG200-15, Levora
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
21
States / cities
Mobile, Alabama • Green Valley, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 17, 2026, 4:59 PM EDT
Completed Phase 3 Interventional

Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS

NCT00161681
View directory record Official record
Conditions
Premenstrual Syndrome
Interventions
Levonorgestrel/Ethinyl Estradiol
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
48
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 17, 2026, 4:59 PM EDT